Earnings summaries and quarterly performance for Viking Therapeutics.
Executive leadership at Viking Therapeutics.
Board of directors at Viking Therapeutics.
Research analysts who have asked questions during Viking Therapeutics earnings calls.
Annabel Samimy
Stifel Financial Corp.
6 questions for VKTX
Also covers: ALT, APLS, CARA +14 more
Hardik Parikh
JPMorgan Chase & Co.
6 questions for VKTX
Also covers: PCRX, RPRX
Jay Olson
Oppenheimer & Co. Inc.
6 questions for VKTX
Also covers: ACAD, AMGN, BIIB +22 more
YJ
Yale Jen
Laidlaw & Company (UK) Ltd.
6 questions for VKTX
Also covers: AFMD, ALDX, ARCT +13 more
Justin Zelin
BTIG, LLC
5 questions for VKTX
Also covers: BCAB, CASI, GLMD +9 more
Mayank Mamtani
B. Riley Securities
5 questions for VKTX
Also covers: AGEN, ALT, ARWR +18 more
Ryan Deschner
Raymond James Financial
5 questions for VKTX
Also covers: APLS, ARDX, ARSP +7 more
JL
Joon Lee
Truist Securities
4 questions for VKTX
Also covers: ADVM, AXSM, CNM +14 more
AH
Andy Hsieh
William Blair & Company
3 questions for VKTX
Also covers: ALT, BYSI, CRDF +8 more
Biren Amin
Piper Sandler Companies
3 questions for VKTX
Also covers: ALLO, APLS, BBIO +5 more
MU
Michael Ulz
Morgan Stanley
3 questions for VKTX
Also covers: ALNY, ARWR, FATE +8 more
RS
Roger Song
Jefferies
3 questions for VKTX
Also covers: AADI, AKBA, ALT +13 more
Steve Seedhouse
Cantor Fitzgerald
3 questions for VKTX
Also covers: BCRX, BOLD, HROW +1 more
AR
Asim Rana
Truist Securities
2 questions for VKTX
Also covers: AXSM, CORT, CPRX +2 more
GF
George Farmer
Scotiabank
2 questions for VKTX
Also covers: ABSI, ADAP, INMB +7 more
JS
Jiale Song
Jefferies Financial Group Inc.
2 questions for VKTX
Also covers: ACRS, CRVS, CTMX +12 more
KP
Kushal Patel
Leerink
2 questions for VKTX
Rohit Bhasin
Morgan Stanley
2 questions for VKTX
Also covers: GUTS, MIRM
TS
Thomas Smith
Leerink Partners
2 questions for VKTX
Also covers: ACRS, ARGX, CLDX +5 more
TH
Tsan-Yu Hsieh
William Blair & Company
2 questions for VKTX
Also covers: AVIR, CRDF, EXEL +6 more
AR
Alexandra Ramsey
William Blair & Company, L.L.C.
1 question for VKTX
Also covers: NKTR
FG
Fiona Gia
Jefferies
1 question for VKTX
JM
Jeet Mukherjee
Leerink Partners
1 question for VKTX
Also covers: ARVN, BCAB, KURA +4 more
NC
Nat Charoensook
Leerink Partners
1 question for VKTX
Also covers: ARGX, IMUX
SS
Steven Seedhouse
Raymond James
1 question for VKTX
Also covers: APLS, BCRX, EDIT +2 more
Recent press releases and 8-K filings for VKTX.
Viking Therapeutics Provides Clinical Pipeline and Trial Updates
VKTX
New Projects/Investments
Product Launch
- Viking Therapeutics' VK2735 (injectable), a GLP-1/GIP dual agonist for obesity, is in its VANQUISH Phase 3 program, with VANQUISH 1 enrollment complete and VANQUISH 2 enrollment expected to complete in 1Q26.
- The VK2735 Oral formulation for obesity successfully achieved its primary endpoint in the VENTURE Oral Phase 2 study, demonstrating up to 14.7% mean weight loss after 13 weeks of treatment.
- The oral VK2735 showed promising tolerability, with the majority of GI-related adverse events being mild to moderate and occurring early in treatment.
- Other pipeline programs include VK2809 for MASH, which reported successful Phase 2b data in 2Q24, and VK0214 for X-ALD, which reported successful Phase 1b data in 4Q24.
Jan 14, 2026, 12:00 PM
Viking Therapeutics Provides Updates on VK2735 Clinical Programs and Financial Position
VKTX
New Projects/Investments
Guidance Update
- Viking Therapeutics is advancing its lead compound, VK2735, a dual GLP-1 and GIP receptor agonist, with Vanquish I Phase III trial enrollment completed and Vanquish II Phase III trial enrollment on track for Q1 2026. Data from these trials are anticipated in the 2027 timeframe.
- The oral formulation of VK2735 completed a Phase II study, demonstrating up to 12% body weight reduction after 13 weeks, with data submission for the European Conference on Obesity in Q2 2026. A sub-Q to oral maintenance study has completed enrollment, with data expected around mid-year or Q3 2026.
- The company maintains a strong financial position, reporting over $700 million in cash as of the end of the third quarter.
- Viking Therapeutics plans to file an Investigational New Drug (IND) for its amylin program in the first quarter of 2026.
- The company's VK2809 program for MASH is currently open for licensing.
Jan 12, 2026, 10:15 PM
Viking Therapeutics Provides Pipeline Update at J.P. Morgan Healthcare Conference
VKTX
New Projects/Investments
Product Launch
- Viking Therapeutics' CEO presented updates on its metabolic disease programs, highlighting VK2735, a dual GLP-1/GIP agonist, with its injectable formulation in Phase III (VANQUISH program), where VANQUISH I enrollment is complete and VANQUISH II is on track for Q1 2026 completion, with data expected in 2027.
- The oral formulation of VK2735 completed its Phase II study, demonstrating up to 12% body weight reduction after 13 weeks, with data submission planned for Q2 2026 and an end-of-Phase II FDA meeting held in December 2025. The company views the oral form as best suited for maintenance therapy.
- The company maintains a strong balance sheet with over $700 million in cash as of the end of Q3 2025.
- Viking Therapeutics plans to file an Investigational New Drug (IND) application for its amylin program in Q1 2026.
Jan 12, 2026, 10:15 PM
Viking Therapeutics Provides Update on VK2735 Programs and Financials
VKTX
New Projects/Investments
Product Launch
Guidance Update
- Viking Therapeutics' lead compound, VK2735, a dual GLP-1 and GIP agonist, is currently in a Phase III program (Vanquish) for obesity and obesity with type 2 diabetes.
- An oral formulation of VK2735 completed a Phase II study in late summer 2025, with data submission planned for the European Conference on Obesity in Q2 2026.
- A Phase I maintenance study for VK2735, exploring subcutaneous to oral transition, has fully enrolled, with data expected around mid-year or Q3 2026.
- The company reported a strong balance sheet with over $700 million in cash as of the end of Q3 2025.
- Phase III readouts for the Vanquish trials are anticipated in the 2027 timeframe.
Jan 12, 2026, 10:15 PM
Viking Therapeutics Announces Publication of Phase 2 VENTURE Trial Results for VK2735
VKTX
New Projects/Investments
- Viking Therapeutics announced the publication of positive results from its Phase 2 VENTURE clinical trial of VK2735 in the journal Obesity.
- The trial demonstrated statistically significant mean body weight reductions of up to 14.7% from baseline after 13 weeks in participants receiving VK2735, with an encouraging safety and tolerability profile.
- VK2735, a dual GLP-1/GIP receptor agonist, is currently being evaluated in the VANQUISH Phase 3 registrational program for obesity.
- The VANQUISH-1 study has completed enrollment of approximately 4,650 adults, and the VANQUISH-2 study is expected to complete enrollment in the first quarter of 2026.
Jan 12, 2026, 12:00 PM
Viking Therapeutics Completes Enrollment in VK2735 Maintenance Dosing Study
VKTX
New Projects/Investments
- Viking Therapeutics has completed patient enrollment in its exploratory maintenance dosing study for VK2735, a dual GLP-1 and GIP receptor agonist being developed for metabolic disorders such as obesity.
- The Phase 1 study, which enrolled approximately 180 adults, is designed to evaluate various subcutaneous and oral maintenance dosing regimens of VK2735 following initial weight loss.
- The primary objectives of the study are to assess the safety, tolerability, and pharmacokinetic profile of VK2735 under these regimens, with results expected later this year.
- This milestone comes as Viking is also conducting two Phase 3 trials for subcutaneous VK2735 (VANQUISH-1 and VANQUISH-2), with VANQUISH-1 having completed enrollment of approximately 4,650 adults.
Jan 8, 2026, 12:00 PM
Viking Therapeutics Appoints Neil Aubuchon as Chief Commercial Officer
VKTX
Management Change
Hiring
- Viking Therapeutics announced the appointment of Neil Aubuchon as its new chief commercial officer on January 7, 2026.
- Mr. Aubuchon brings over two decades of biopharmaceutical industry experience, including leadership roles at AbCellera, Amgen, and Eli Lilly, with a focus on cardiometabolic and general medicine portfolios.
- His primary responsibility will be to lead the commercialization strategy for VK2735, Viking's GLP-1/GIP dual agonist currently in Phase 3 trials for obesity, and to engage with potential strategic partners.
Jan 7, 2026, 12:00 PM
VKTX Provides Updates on Obesity and Metabolic Disease Programs
VKTX
New Projects/Investments
- VKTX's oral VK2735 (GLP-1/GIP dual agonist for obesity) successfully completed its VENTURE Phase 2 study, achieving its primary endpoint with up to 14.7% mean weight loss after 13 weeks and demonstrating promising tolerability. An End of Phase 2 meeting with the FDA is scheduled for later this year.
- The injectable VK2735 formulation is progressing into Phase 3, with two VANQUISH studies initiated in 2Q25. Enrollment for VANQUISH 1 is complete, and VANQUISH 2 enrollment is expected to conclude in 1Q26.
- Other pipeline developments include successful Phase 2b data for VK2809 (MASH) reported in 2Q24 and successful Phase 1b data for VK0214 (X-ALD) reported in 4Q24. An Investigational New Drug (IND) application for an Amylin agonist for obesity is planned for 1Q26.
Nov 19, 2025, 12:00 PM
Viking Therapeutics Provides Update on VK2735 Obesity Programs and Financial Position
VKTX
New Projects/Investments
Guidance Update
- Viking Therapeutics is advancing VK2735, a GLP-1 GIP dual agonist, with its subcutaneous formulation in Phase III for obesity and an oral formulation having completed a Phase II study.
- Enrollment for the VANQUISH I Phase III study has been completed, and VANQUISH II is expected to complete enrollment in Q1 2026.
- The oral formulation of VK2735 demonstrated up to 12.2% body weight reduction after 13 weeks in its Phase II study, with an end-of-Phase II meeting with the FDA planned by year-end 2025.
- The company reported over $700 million in cash at the end of the third quarter, which is expected to fund operations through the VANQUISH Phase III data readouts.
Nov 19, 2025, 8:00 AM
Viking Therapeutics Updates on VK2735 Obesity Programs and Financials
VKTX
Product Launch
New Projects/Investments
- Viking Therapeutics' lead drug, VK2735, a GLP-1, GIP dual agonist for obesity, is progressing with both subcutaneous and oral formulations.
- The subcutaneous VK2735 is in Phase III (VANQUISH program), with VANQUISH-1 (obesity) having completed enrollment and VANQUISH-2 (obesity and type 2 diabetes) expected to complete enrollment in Q1 2026.
- The oral formulation of VK2735 recently completed a Phase II study, demonstrating up to 12.2% body weight reduction after 13 weeks and excellent tolerability; the company plans an end-of-Phase II meeting with the FDA by the end of 2025.
- The company reported over $700 million in cash at the end of Q3 2025, which is expected to fund operations through the VANQUISH Phase III data readouts.
Nov 19, 2025, 8:00 AM
Quarterly earnings call transcripts for Viking Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more